Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short Interest

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) was the recipient of a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 15,251 shares, a growth of 33.9% from the February 26th total of 11,389 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 18,725 shares, the short-interest ratio is currently 0.8 days.

Analyst Upgrades and Downgrades

PHAR has been the topic of several recent analyst reports. Weiss Ratings lowered Pharming Group from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 13th. Zacks Research lowered Pharming Group from a “hold” rating to a “strong sell” rating in a report on Thursday, March 12th. HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a report on Tuesday, March 24th. Oppenheimer reaffirmed an “outperform” rating and set a $41.00 target price (down from $42.00) on shares of Pharming Group in a research report on Friday, March 13th. Finally, Wall Street Zen upgraded Pharming Group to a “strong-buy” rating in a report on Saturday, December 27th. Two investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Pharming Group currently has an average rating of “Hold” and a consensus target price of $39.00.

Pharming Group Stock Performance

Shares of PHAR opened at $16.01 on Tuesday. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of 1,601.00 and a beta of 0.04. The company has a current ratio of 2.59, a quick ratio of 2.03 and a debt-to-equity ratio of 0.33. The stock has a 50 day moving average of $16.72 and a 200 day moving average of $16.18. Pharming Group has a 12 month low of $7.50 and a 12 month high of $21.34.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, March 12th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.08). The business had revenue of $106.50 million for the quarter, compared to the consensus estimate of $111.76 million. Pharming Group had a return on equity of 1.08% and a net margin of 0.71%. As a group, sell-side analysts forecast that Pharming Group will post -0.2 earnings per share for the current year.

Hedge Funds Weigh In On Pharming Group

Large investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC bought a new stake in shares of Pharming Group in the 2nd quarter worth approximately $32,000. SmartHarvest Portfolios LLC bought a new stake in Pharming Group during the fourth quarter worth about $224,000. Millennium Management LLC bought a new stake in shares of Pharming Group in the 4th quarter worth approximately $360,000. Finally, NewEdge Advisors LLC raised its position in Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after acquiring an additional 28,615 shares during the period. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.